Version May 2024
Note: Vexol has been discontinued in the United States since September 2016.
Anterior uveitis: Ophthalmic: Instill 1 to 2 drops in conjunctival sac of affected eye every hour during waking hours for the first week, then 1 drop every 2 hours during waking hours of the second week, and then taper until uveitis is resolved.
Postoperative ocular inflammation: Ophthalmic: Instill 1 to 2 drops in conjunctival sac of affected eye 4 times daily beginning 24 hours after surgery and continuing through the first 2 weeks of the postoperative period.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 5%:
Central nervous system: Foreign body sensation of eye
Ophthalmic: Blurred vision, eye discharge, eye discomfort, eye pain, eye pruritus, increased intraocular pressure, ocular hyperemia
<2%:
Cardiovascular: Hypotension
Central nervous system: Headache
Gastrointestinal: Dysgeusia
Respiratory: Pharyngitis, rhinitis
Frequency not defined:
Infection: Secondary ocular infection
Ophthalmic: Cataract, eye disease (defects in visual activity), eye perforation, optic nerve damage
<1%, postmarketing, and/or case reports: Anterior chamber fibrin deposition, brow ache, conjunctival edema, corneal edema, corneal erosion, corneal infiltrates, corneal staining, corneal ulcer, crusting of eyelid, eye irritation, keratitis, lacrimation, ocular edema, photophobia, sticky sensation of eye, xerophthalmia
Hypersensitivity to rimexolone or any component of the formulation; acute untreated purulent ocular infections; viral diseases of the cornea and conjunctiva (eg, epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial or fungal infections of the eye
Concerns related to adverse effects:
• Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.
• Corneal thinning: Various ophthalmic disorders, as well as prolonged use of corticosteroids, may result in corneal and scleral thinning. Continued use in a patient with thinning may result in perforation.
• Glaucoma: Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP) and/or glaucoma; damage to the optic nerve; and defects in visual acuity and fields of vision. Use with caution in patients with glaucoma; monitor IOP in any patient receiving treatment for ≥10 days.
• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection (including fungal infections). Acute purulent ocular infections may be masked or exacerbated with use. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.
Special populations:
• Contact lens wearers: Some preparations contain benzalkonium chloride which may be adsorbed by contact lenses.
Other warnings/precautions:
• Appropriate use: Patients should be re-evaluated if symptoms fail to improve after 2 days. Initial prescription and renewal of medication should be made by healthcare provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). Corticosteroids should not be used to treat ocular herpes simplex. Use of same bottle in both eyes of postoperative patients is not recommended.
Vexol has been discontinued in the United States for more than 1 year.
Yes
Suspension (Vexol Ophthalmic)
1% (5 mL): $102.30
Disclaimer: The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.
For topical ophthalmic use only; to avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Shake well before using. The use of the same bottle for both eyes is not recommended in surgical patients.
Ophthalmic inflammatory conditions: Treatment of postoperative inflammation following ocular surgery; treatment of anterior uveitis
Vexol may be confused with VoSoL
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Risk C: Monitor therapy
Adverse events have been observed in animal reproduction studies following subcutaneous administration. The amount of rimexolone absorbed systemically following ophthalmic administration is low (<80 to 470 pg/mL).
It is not known if rimexolone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.
Intraocular pressure and periodic examination of lens (with prolonged use ≥10 days)
Suppresses the inflammatory response by inhibiting edema, capillary dilation, leukocyte migration and scar formation.
Absorption: Through aqueous humor
Metabolism: Hepatic for any amount of drug absorbed
Half-life elimination: 1 to 2 hours
Excretion: Urine and feces (>80%)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
